PATENT CLAIM ANALYSIS

Application Number: 15980515
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2019-04
Patent Classification: ["514", "210200"]

Abstract:
Disclosed herein are reversible and irreversible inhibitors of Bruton's tyrosine kinase (Btk). Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are described, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

Claim (Index 21):
A compound, wherein the compound is (R)-3-(1-(4-tert-butylbenzoyl)piperidin-3-ylamino)-5-(4-(morpholine-4-carbonyl)phenylamino)-1,2,4-triazine-6-carboxamide.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 93.0
- Lexical Diversity: 1.5
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14559889', '15173182', '14790978', '14770438', '14375765']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7812094931391014
- 35 USC 102 Novelty (BERT): 0.5209570757381436
- Combined Prediction Score: 0.7551842513990056
- Mean Citation Score: 265.65803
- Max Citation Score: 332.1877
- Similarity Product: 309.0923094171643

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test